# Nafarelin (Synarel)

> Intranasal GnRH agonist for endometriosis and central precocious puberty.

Source: https://peptides.cafe/peptide/nafarelin
Category: GnRH Agonist · Endocrine
Tag: FDA-Approved · Endocrine

## Mechanism
Decapeptide GnRH agonist administered intranasally; sustained receptor occupancy downregulates pituitary GnRH receptors, suppressing gonadotropin and sex steroid output.

## Research areas
- Endometriosis
- Central precocious puberty

## Common research protocols
- Intranasal: 200 mcg per spray; one spray in each nostril twice daily for endometriosis.

## Study summaries
- "Nafarelin for endometriosis" — Fertility & Sterility (1990): Comparable pain and lesion reduction to danazol with different side-effect profile.

## Considerations
- FDA-approved.
- Hypoestrogenic symptoms; limit treatment course for bone health.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.